Cargando…
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217764/ https://www.ncbi.nlm.nih.gov/pubmed/35412171 http://dx.doi.org/10.1007/s11523-022-00881-2 |
| _version_ | 1784731726167146496 |
|---|---|
| author | Shimizu, Toshio Kuboki, Yasutoshi Lin, Chia-Chi Yonemori, Kan Yanai, Tomoko Faller, Douglas V. Dobler, lwona Gupta, Neeraj Sedarati, Farhad Kim, Kyu-pyo |
| author_facet | Shimizu, Toshio Kuboki, Yasutoshi Lin, Chia-Chi Yonemori, Kan Yanai, Tomoko Faller, Douglas V. Dobler, lwona Gupta, Neeraj Sedarati, Farhad Kim, Kyu-pyo |
| author_sort | Shimizu, Toshio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9217764 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92177642022-06-24 Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Shimizu, Toshio Kuboki, Yasutoshi Lin, Chia-Chi Yonemori, Kan Yanai, Tomoko Faller, Douglas V. Dobler, lwona Gupta, Neeraj Sedarati, Farhad Kim, Kyu-pyo Target Oncol Correction Springer International Publishing 2022-04-12 2022 /pmc/articles/PMC9217764/ /pubmed/35412171 http://dx.doi.org/10.1007/s11523-022-00881-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Shimizu, Toshio Kuboki, Yasutoshi Lin, Chia-Chi Yonemori, Kan Yanai, Tomoko Faller, Douglas V. Dobler, lwona Gupta, Neeraj Sedarati, Farhad Kim, Kyu-pyo Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies |
| title | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies |
| title_full | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies |
| title_fullStr | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies |
| title_full_unstemmed | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies |
| title_short | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies |
| title_sort | correction to: a phase 1 study of sapanisertib (tak-228) in east asian patients with advanced nonhematological malignancies |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217764/ https://www.ncbi.nlm.nih.gov/pubmed/35412171 http://dx.doi.org/10.1007/s11523-022-00881-2 |
| work_keys_str_mv | AT shimizutoshio correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT kubokiyasutoshi correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT linchiachi correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT yonemorikan correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT yanaitomoko correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT fallerdouglasv correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT doblerlwona correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT guptaneeraj correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT sedaratifarhad correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies AT kimkyupyo correctiontoaphase1studyofsapanisertibtak228ineastasianpatientswithadvancednonhematologicalmalignancies |